Shefali  Agarwal net worth and biography

Shefali Agarwal Biography and Net Worth

Insider of Epizyme
Dr. Shefali Agarwal is Epizyme’s Chief Medical Officer. Prior to joining the company in 2018, Shefali held leadership positions across medical research, clinical development, clinical operations and medical affairs. She most recently served as chief medical officer at SQZ Biotech, where she built and led the clinical development organization, which included clinical research operations and the regulatory function. Before SQZ Biotech, Shefali also held leadership positions at Curis and Tesaro. At Curis, she oversaw the Phase 2 study for its dual HDAC/PI3K inhibitor in diffuse large B-cell lymphoma, and the Phase 1 study in solid tumors for its oral checkpoint inhibitor. At Tesaro, she led the NDA and EMA submissions for ZEJULA® (niraparib) in ovarian cancer. Shefali has also held positions of increasing responsibility at Covidien, AVEO Oncology and Pfizer.

In addition to receiving her medical degree, Shefali holds a master’s of public health and a master’s of science in business. She currently sits on the Board of Directors of Fate Therapeutics.

What is Shefali Agarwal's net worth?

The estimated net worth of Shefali Agarwal is at least $2,704.80 as of June 7th, 2022. Dr. Agarwal owns 1,840 shares of Epizyme stock worth more than $2,705 as of March 28th. This net worth estimate does not reflect any other assets that Dr. Agarwal may own. Learn More about Shefali Agarwal's net worth.

How do I contact Shefali Agarwal?

The corporate mailing address for Dr. Agarwal and other Epizyme executives is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Epizyme can also be reached via phone at (617) 229-5872 and via email at [email protected]. Learn More on Shefali Agarwal's contact information.

Has Shefali Agarwal been buying or selling shares of Epizyme?

Shefali Agarwal has not been actively trading shares of Epizyme in the last ninety days. Most recently, Shefali Agarwal sold 2,639 shares of the business's stock in a transaction on Wednesday, February 2nd. The shares were sold at an average price of $1.37, for a transaction totalling $3,615.43. Learn More on Shefali Agarwal's trading history.

Who are Epizyme's active insiders?

Epizyme's insider roster includes Shefali Agarwal (Insider), Robert Bazemore Jr. (CEO), Joseph Beaulieu (Insider), Jeffery Kutok (Insider), Pablo Legorreta (Director), and David Mott (Director). Learn More on Epizyme's active insiders.

Shefali Agarwal Insider Trading History at Epizyme

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/2/2022Sell2,639$1.37$3,615.43View SEC Filing Icon  
1/26/2022Sell2,922$2.02$5,902.44View SEC Filing Icon  
12/6/2021Sell1,780$2.93$5,215.40View SEC Filing Icon  
2/4/2021Sell969$11.21$10,862.49104,341View SEC Filing Icon  
12/3/2020Sell2,522$13.54$34,147.8876,089View SEC Filing Icon  
1/27/2020Sell2,630$20.44$53,757.2063,276View SEC Filing Icon  
1/24/2020Sell1,843$24.64$45,411.5263,276View SEC Filing Icon  
See Full Table

Shefali Agarwal Buying and Selling Activity at Epizyme

This chart shows Shefali Agarwal's buying and selling at Epizyme by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Epizyme Company Overview

Epizyme logo
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.47
Low: $1.47
High: $1.47

50 Day Range

MA: $1.47
Low: $1.47
High: $1.52

2 Week Range

Now: $1.47
Low: $0.41
High: $5.80

Volume

7,960 shs

Average Volume

3,225,203 shs

Market Capitalization

$247.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A